Evidence map›Paper›PMID 25887548›Full record

ArticleBMC bioinformatics2015

Systematic computation with functional gene-sets among leukemic and hematopoietic stem cells reveals a favorable prognostic signature for acute myeloid leukemia.

Xinan Holly Yang, Meiyi Li, Bin Wang, Wanqi Zhu, Aurelie Desgardin, Kenan Onel, Jill de Jong, Jianjun Chen, Luonan Chen, John M Cunningham

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Xinan Holly YangDepartment of Pediatrics, and Comer Children's Hospital, Section of Hematology/Oncology, The University of Chicago, 900 East 57th Street, KCBD Room 5121, Chicago, Illinois, 60637, USA. xyang2@uchicago.edu.
Meiyi LiKey Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. limeiyi@sibs.ac.cn.
Bin WangDepartment of Pediatrics, and Comer Children's Hospital, Section of Hematology/Oncology, The University of Chicago, 900 East 57th Street, KCBD Room 5121, Chicago, Illinois, 60637, USA. bwang@peds.bsd.uchicago.edu.
Wanqi ZhuLaboratory Schools, The University of Chicago, Chicago, USA. 1213.ghs@gmail.com.
Aurelie DesgardinDepartment of Pediatrics, and Comer Children's Hospital, Section of Hematology/Oncology, The University of Chicago, 900 East 57th Street, KCBD Room 5121, Chicago, Illinois, 60637, USA. adesgard@bsd.uchicago.edu.
Kenan OnelDepartment of Pediatrics, and Comer Children's Hospital, Section of Hematology/Oncology, The University of Chicago, 900 East 57th Street, KCBD Room 5121, Chicago, Illinois, 60637, USA. konel@peds.bsd.uchicago.edu.
Jill de JongDepartment of Pediatrics, and Comer Children's Hospital, Section of Hematology/Oncology, The University of Chicago, 900 East 57th Street, KCBD Room 5121, Chicago, Illinois, 60637, USA. jdejong@peds.bsd.uchicago.edu.
Jianjun ChenDepartment of Medicine, The University of Chicago, Chicago, USA. jchen@medicine.bsd.uchicago.edu.
Luonan ChenKey Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. lnchen@sibs.ac.cn.
John M CunninghamDepartment of Pediatrics, and Comer Children's Hospital, Section of Hematology/Oncology, The University of Chicago, 900 East 57th Street, KCBD Room 5121, Chicago, Illinois, 60637, USA. jmcunningham@uchicago.edu.
University of Chicago · USChinese Academy of Sciences · CN

Funding

Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemiaR01CA182528 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7M
The role and functional mechanism of TET1 in MLL-rearranged leukemiaR01CA178454 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7M
Modeling MicroRNA-Target Functional Networks for Acute Myeloid Leukemia PrognosisR21CA167305 · NCI · UNIVERSITY OF CHICAGO · PI YANG, XINAN HOLLY · 2013 to 2014
$370k
NCATS NIH HHS UL1 TR000430NCI NIH HHS R01 CA178454NCI NIH HHS R01 CA182528NCI NIH HHS R21 CA167305NCI NIH HHS R21 CA167305-01A1
6 · The paper itself

Abstract

backgroundGenes that regulate stem cell function are suspected to exert adverse effects on prognosis in malignancy. However, diverse cancer stem cell signatures are difficult for physicians to interpret and apply clinically. To connect the transcriptome and stem cell biology, with potential clinical applications, we propose a novel computational "gene-to-function, snapshot-to-dynamics, and biology-to-clinic" framework to uncover core functional gene-sets signatures. This framework incorporates three function-centric gene-set analysis strategies: a meta-analysis of both microarray and RNA-seq data, novel dynamic network mechanism (DNM) identification, and a personalized prognostic indicator analysis. This work uses complex disease acute myeloid leukemia (AML) as a research platform.

resultsWe introduced an adjustable "soft threshold" to a functional gene-set algorithm and found that two different analysis methods identified distinct gene-set signatures from the same samples. We identified a 30-gene cluster that characterizes leukemic stem cell (LSC)-depleted cells and a 25-gene cluster that characterizes LSC-enriched cells in parallel; both mark favorable-prognosis in AML. Genes within each signature significantly share common biological processes and/or molecular functions (empirical p = 6e-5 and 0.03 respectively). The 25-gene signature reflects the abnormal development of stem cells in AML, such as AURKA over-expression. We subsequently determined that the clinical relevance of both signatures is independent of known clinical risk classifications in 214 patients with cytogenetically normal AML. We successfully validated the prognosis of both signatures in two independent cohorts of 91 and 242 patients respectively (log-rank p < 0.0015 and 0.05; empirical p < 0.015 and 0.08).

conclusionThe proposed algorithms and computational framework will harness systems biology research because they efficiently translate gene-sets (rather than single genes) into biological discoveries about AML and other complex diseases.

Indexed as

Gene Regulatory NetworksTranscriptomeAlgorithmsGene Expression ProfilingHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteNeoplastic Stem CellsPrognosis

Identifiers

PMID25887548
PMCPMC4376348
OpenAlexW2059592506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.